Pierre Socié

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Frequency of Recovery from Complete Atrioventricular Block After Cardiac Surgery

Pierre Socié, Florence Nicot, Pierre Baudinaud et al. · The American Journal of Cardiology · 2017 · 30 citations

Cardiac Surgery, Cardiac Anaesthesia, Cardiothoracic Surgery +9

A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk)

Elham Kayvanpour, Arjan Sammani, Farbod Sedaghat‐Hamedani et al. · International Journal of Cardiology · 2021 · 21 citations

Cardiomyopathy, Heart Failure, Novel Risk Model +12

Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis

Pierre Socié, Anouar Benmalek, Cécile Cauquil et al. · Amyloid · 2023 · 12 citations · Full text